BIT
GEVA

BlackRock Institutional Trust’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BlackRock Institutional Trust’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-610,716
Closed -$59.6M – 4028
2015
Q1 		$59.6M Buy
610,716
+29,735
+5% +$3.15M 0.01% 1218
2014
Q4 		$53.9M Sell
580,981
-12,228
-2% -$965K 0.01% 1247
2014
Q3 		$40.8M Buy
593,209
+3,084
+0.5% +$221K 0.01% 1392
2014
Q2 		$61.8M Buy
590,125
+7,816
+1% +$665K 0.01% 1182
2014
Q1 		$48.3M Buy
582,309
+33,516
+6% +$3.1M 0.01% 1302
2013
Q4 		$35.5M Buy
548,793
+130,177
+31% +$7.73M 0.01% 1513
2013
Q3 		$26.5M Buy
418,616
+24,031
+6% +$1.18M 0.01% 1647
2013
Q2 		$16.6M Buy
+394,585
New +$18M ﹤0.01% 1950

BlackRock Institutional Trust's GEVA Position: Q2 2015 in Review

BlackRock Institutional Trust sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 610,716 shares — an estimated $59.6M sold.

BlackRock Institutional Trust first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $61.8M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BlackRock Institutional Trust reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BlackRock Institutional Trust sold 610,716 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $59.6M.
  • BlackRock Institutional Trust first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • BlackRock Institutional Trust's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $61.8M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BlackRock Institutional Trust's 13F filing for Q2 2015, filed 7 Aug 2015.